Zobrazeno 1 - 9
of 9
pro vyhledávání: '"I P, van Munster"'
Autor:
I P Van Munster, Fokko M. Nagengast
Publikováno v:
Scandinavian Journal of Gastroenterology. 28:80-86
Diet is an important factor in the development of colonic cancer. Fibre has been shown to decrease this risk. Part of this protective effect is probably mediated by colonic fermentation. About 10% of starch in the normal diet escapes digestion and ab
Autor:
L G M, van Rossum, A F, van Rijn, I P, van Munster, J B M J, Jansen, P, Fockens, R J F, Laheij, E, Dekker
Publikováno v:
The Netherlands journal of medicine. 67(5)
The aim of colorectal cancer screening is to improve prognosis by the detection of early cancer and precursor stages. We compared the stage distribution of asymptomatic colorectal cancer patients detected by a positive immunochemical or guaiac-based
Publikováno v:
The Netherlands journal of medicine. 66(11)
Publikováno v:
Digestive diseases and sciences. 39(4)
Resistant starch is by definition that part of starch that escapes digestion in the small bowel. Cecal fermentation of resistant starch into short-chain fatty acids will result subsequently in a decrease in pH. Thus, resistant starch may have the sam
Autor:
I. P. Van Munster, H M de Boer, Fokko M. Nagengast, J.M.M. van Amelsvoort, Martijn B. Katan, M C Jansen, A. F. J. De Haan
Publikováno v:
American Journal of Clinical Nutrition 59 (1994)
American Journal of Clinical Nutrition, 59, 626-630
American Journal of Clinical Nutrition, 59, 626-630
Colonic fermentation of dietary carbohy- drates and fiber might produce a protective effect against the development of large bowel cancer. Resistant starch, ie, starch that escapes small bowel digestion, is a candidate fermentable substrate that has
Publikováno v:
European journal of clinical investigation. 23(12)
Soluble secondary bile acids in the colon are supposed to be cytotoxic for normal colonic cells, resulting in an increased compensatory proliferation of colonic crypt cells, which is associated with an increased risk for colonic cancer. We developed
Publikováno v:
Pharmaceutisch weekblad. Scientific edition. 14(4)
Interferon alpha is the only available therapy for patients with chronic hepatitis B. With interferon alpha 3–15 MU thrice weekly or 5 MU daily during 3–6 months one-third of the patients achieve seroconversion of HBeAg and HBV-DNA together with
Publikováno v:
European Journal of Cancer Prevention. 2:12
Autor:
E H, van Haren, W P, Hopman, I P, van Munster, C L, van Herwaarden, U J, van Haelst, J H, van Tongeren
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 132(53)